Therapeutic area intelligence for Vasopressin Antagonist with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 3
Catalysts: 0
Companies: 2

Companies

Alkem Labs →

Teva →

Assets

Tolvaptan →

Recent signals(3)

RegulatoryJuly 28, 2026

FDA Approval Process Update for Tolvaptan by Alkem Labs

The FDA has received an application (ANDA220147) for Tolvaptan from Alkem Labs, currently under standard review.

StrategyJuly 25, 2026

FDA Grants Approval for Teva's Tolvaptan ANDA216933

Teva Pharmaceuticals has received an approval for their Abbreviated New Drug Application (ANDA216933) for Tolvaptan.

StrategyJuly 5, 2026

FDA Accepts ANDA for Tolvaptan by Alkem Labs

The FDA has accepted the Abbreviated New Drug Application (ANDA) for Tolvaptan submitted by Alkem Labs.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.